Key result
SM-10906 binds to [3H]iloprost binding sites and dose-dependently enhances cAMP levels in human vascular endothelial cells, indicating anti-platelet and cytoprotective actions.
SM-10906 binds to iloprost receptors and increases intracellular cAMP in human platelets and endothelial cells, indicating potential anti-platelet and cytoprotective effects.
Answers are grounded in this paper and cite their sources.
SM-10906 may warrant further preclinical development; leaves open any clinical role pending human trials.
SM-10902 (( + )-methyl [2-[(2R,3aS,4R,5R,6aS)-octahydro-5-hydroxy-4-[(E)-(3S,5S)-3-hy-droxy-5-methyl-l-nonenyl]-2-pentalenyl]ethoxy]acetate) and its free acid, SM-10906 are new stable 3-oxa-methano prostaglandin (PG) Ii analogs.. Their affinities for [3H]iloprost and [3H]PGE2 binding sites in human platelets and human umbilical vascular endothelial cells were compared with those of the PGI2 analog iloprost, PGEi and PGE2 by the radioligand binding assay method. The cyclic AMP (cAMP) synthesis activity of these drugs were also determined in human umbilical vascular endothelial cells. We found that SM-10906 apparently displaced [3H]iloprost binding to the membrane fractions in those cells since the pKi values were 6.30 in platelets, 7.52 in vein endothelial cells and 6.31 in the arterial endothelial cells. The pKj values of SM-10906 for [3H]PGE2 binding sites were significantly lower than those obtained for [3H]il-oprost binding. SM-10902, which is a prodrug of SM-10906, showed low affinity for [3H]iloprost binding sites in those cells. SM-10906 also dose-dependently enhanced the cAMP level in the vascular endothelial cells. Thus, these findings indicate that SM-10906 binds to [3H]iloprost binding sites and exhibits pharmacological functions such as an anti-platelet action and a cytoprotective action in endothelial cells through the elevation of intracellular cAMP contents.
No takes yet. Share an insight, caveat, or question.
Hiroi et al. (1997) studied this question. SM-10906 and SM-10902 vs. iloprost, PGE1, PGE2 was evaluated on Affinity for [3H]iloprost and [3H]PGE2 binding sites and cAMP synthesis activity. SM-10906 binds to [3H]iloprost binding sites and dose-dependently enhances cAMP levels in human vascular endothelial cells, indicating anti-platelet and cytoprotective actions.
Synapse has enriched 10 related papers. Consider them for comparative context: